NeuroDiagnostics, LLC New Alzheimer’s Assay Granted Breakthrough Device Designation by U.S. Food and Drug Administration
DISCERN™ is the most accurate, least invasive and most cost effective test for identifying Alzheimer’s Disease (Rockville, MD) October 15, 2018 – NeuroDiagnostics, LLC, a privately held neurological diagnostics company, announced today that the US Food and Drug Administration (FDA) has granted…Read More